Videos
Press Releases
22 Sep 2022
EORTC Quality of Life Group celebrating 40 years
31 Aug 2022
EORTC Item Library provides considerable coverage of CTCAE side effects, new study finds
27 Jun 2022
PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation
17 Mar 2022
MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
Latest Newsletters
News
20 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
19 Oct 2023
EORTC & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer
17 Oct 2023
EORTC’s presence at ESMO 2023
4 Oct 2023
The EU funded project LEGATO officially started
26 Sep 2023
EORTC strategic meeting with Middle Eastern Ambassadors
22 Sep 2023
EORTC Quality of Life Group projects to be presented at ISOQOL 2023
17 Jul 2023
Celebrating Sarcoma Awareness Month with the start of EU-funded STREXIT 2 project study
30 Jun 2023
“Best Proposal in Medicine” award received by EORTC at the PTCOG 61 Conference
16 Jun 2023
Long-term efficacy and safety outcomes of the EORTC/LYSA/FIL H10 trial assessing early PET-scan adapted treatment of limited stage Hodgkin lymphoma
9 Jun 2023
Joint Statement: health organisations define EHDS’ opt out required for life saving research
